Brian M. Stuglik, a director at Puma Biotechnology, Inc. (NASDAQ:PBYI), sold 8,100 shares of the company’s common stock for a total of $58,311 on June 12, 2026. The shares were sold at prices ranging from $6.98 to $7.32 per share. The stock has delivered strong returns recently, climbing over 104% in the past year and trading near its 52-week high of $7.90. According to InvestingPro analysis, PBYI appears undervalued at current levels, with the stock featured on the platform’s Most Undervalued list. This transaction was conducted under a pre-arranged 10b5-1 trading plan, which was adopted on March 12, 2025.
The sale followed an acquisition of 27,000 shares of common stock by Mr. Stuglik on June 11, 2026. These shares were granted as Restricted Stock Units (RSUs) that vest in full on the earlier of the one-year anniversary of the grant date or the date of the annual shareholder meeting following the grant date, contingent upon Mr. Stuglik’s continued service with the Issuer.
Following these transactions, Mr. Stuglik directly holds 113,858 shares of Puma Biotechnology common stock. InvestingPro Tips highlight that the company has been profitable over the last twelve months and holds more cash than debt on its balance sheet—two of eight total tips available to subscribers seeking deeper insights into PBYI’s financial health. The Form 4 report detailing these transactions was filed with the Securities and Exchange Commission on June 15, 2026.
In other recent news, Puma Biotechnology Inc. reported its first-quarter 2026 earnings, which did not meet analyst expectations. The company disclosed a net loss per share of -$0.04, falling short of the anticipated breakeven forecast of $0.00. Additionally, Puma Biotech’s revenue for the quarter was $44.8 million, which was below the expected $49 million, resulting in a revenue surprise of -8.57%. These results highlight the challenges the company faced in meeting financial forecasts. The earnings announcement is a significant development for investors monitoring Puma Biotech’s financial health. This recent update may influence future analyses and projections by financial firms. As investors digest these figures, the focus will likely remain on how the company plans to address these financial shortfalls in upcoming quarters.Puma BiotechFollowAnalyze PBYIIncluded in our AI-picked strategies·Review strategies7.09▼-0.240(-3.27%)Closed·15:59:59·USD7.070.000(0.00%)After Hours·16:10:041D1W1M6M1Y5YMaxCreated with Highcharts 11.4.813:3014:0014:3015:0015:3016:0017:0018:3019:0019:306.877.27.4Analyze PBYIThis article was generated with the support of AI and reviewed by an editor. For more information see our T&C.Spot the trade on PBYI before it happensMost traders know the market. The hard part is the moment — which stock, right now, at what price.Chart analysis handles that.Our Vision AI scans your charts, spots the pattern before it plays out, and hands you the complete setup: entry, exit, done in under 60 seconds. Investors are already reporting a high accuracy rate, even on penny stocks.Flash Sale - Price Goes Up Soon